Literature DB >> 19330058

Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology.

Richard M Goldberg, John L Marshall, Jaffer A Ajani, Philip A Philip, Eileen M O'Reilly, Alan P Venook.   

Abstract

Year:  2007        PMID： 19330058      PMCID： PMC2659796     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  12 in total

1.  Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

Authors:  Ralph H Hruban; N Volkan Adsay; Jorge Albores-Saavedra; Miriam R Anver; Andrew V Biankin; Gregory P Boivin; Emma E Furth; Toru Furukawa; Alison Klein; David S Klimstra; Gunter Kloppel; Gregory Y Lauwers; Daniel S Longnecker; Jutta Luttges; Anirban Maitra; G Johan A Offerhaus; Lucía Pérez-Gallego; Mark Redston; David A Tuveson
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.

Authors:  A C Tersmette; G M Petersen; G J Offerhaus; F C Falatko; K A Brune; M Goggins; E Rozenblum; R E Wilentz; C J Yeo; J L Cameron; S E Kern; R H Hruban
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

3.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

4.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Authors:  Ghassan K Abou-Alfa; Lawrence Schwartz; Sergio Ricci; Dino Amadori; Armando Santoro; Arie Figer; Jacques De Greve; Jean-Yves Douillard; Chetan Lathia; Brian Schwartz; Ian Taylor; Marius Moscovici; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

5.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

Authors:  Winnie Yeo; Tony S Mok; Benny Zee; Thomas W T Leung; Paul B S Lai; Wan Y Lau; Jane Koh; Frankie K F Mo; Simon C H Yu; Anthony T Chan; Pun Hui; Brigette Ma; Kwok C Lam; Wing M Ho; Herman T Wong; Amanda Tang; Philip J Johnson
Journal:  J Natl Cancer Inst       Date:  2005-10-19       Impact factor: 13.506

6.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

7.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

8.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

9.  Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

Authors:  Robert G Gish; Camillo Porta; Lucian Lazar; Paul Ruff; Ronald Feld; Adina Croitoru; Lynn Feun; Krzysztof Jeziorski; John Leighton; José Gallo; Gerard T Kennealey
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

10.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.